Characterization of a Hypoallergenic Recombinant Bet v 1 Variant as a Candidate for Allergen-Specific Immunotherapy

2007 ◽  
Vol 145 (3) ◽  
pp. 193-206 ◽  
Author(s):  
H. Kahlert ◽  
R. Suck ◽  
B. Weber ◽  
A. Nandy ◽  
M. Wald ◽  
...  
Keyword(s):  
Specific Immunotherapy ◽  
Allergen Specific Immunotherapy ◽  
Bet V 1

scholarly journals Preparation and Characterization of a Glycyrrhizic Acid-Based Drug Delivery System for Allergen-Specific Immunotherapy

2021 ◽  
Author(s):  
Ekaterina Pashkina ◽  
Veronika Evseenko ◽  
Natalya Dumchenko ◽  
Maxim Zelikman ◽  
Alina Aktanova ◽  
...  
Keyword(s):  
Side Effects ◽  
Delivery System ◽  
Glycyrrhizic Acid ◽  
Specific Immunotherapy ◽  
Allergic Diseases ◽  
Treg Cells ◽  
Delivery Systems ◽  
New Drugs ◽  
Allergen Specific Immunotherapy

The most effective method of treating allergic diseases, aimed not at relieving symptoms, but at eliminating the cause of the disease, is allergen-specific immunotherapy (AIT). To reduce the risk of side effects and improve the delivery of allergens to the mucosa, various delivery systems, such as liposomes, dendrimers, nanoparticles, etc., can be used. To date, there are data on the creation of delivery systems based on glycyrrhizic acid (GA) and its derivatives, but such a delivery system has not been used for allergen-specific therapy until now. At the same time, it is known that GA has an anti-inflammatory effect, shifts the balance towards Th1, and increases the number of Treg cells, which means that in the future it can enhance the anti-allergic effect of AIT and reduce the risk of unwanted side effects. Thus, the study of the immunomodulatory effect of supramolecular complexes (micelles) of GA with extracts of allergens seems to be very promising for the development of new drugs for AIT.

Immunologic characterization of 3 murine regimens of allergen-specific immunotherapy

2015 ◽  
Vol 135 (5) ◽  
pp. 1341-1351.e7 ◽  
Author(s):  
Ellen Mueller Fox ◽  
Marina N. Torrero ◽  
Holly Evans ◽  
Edward Mitre
Keyword(s):  
Specific Immunotherapy ◽  
Allergen Specific Immunotherapy

IgE and allergen-specific immunotherapy-induced IgG4recognize similar epitopes of Bet v 1, the major allergen of birch pollen

2016 ◽  
Vol 47 (5) ◽  
pp. 693-703 ◽  
Author(s):  
N. Groh ◽  
C. S. von Loetzen ◽  
B. Subbarayal ◽  
C. Möbs ◽  
L. Vogel ◽  
...  
Keyword(s):  
Specific Immunotherapy ◽  
Birch Pollen ◽  
Major Allergen ◽  
Allergen Specific Immunotherapy ◽  
Bet V 1

scholarly journals Characterization of mutants of a highly cross-reactive calcium-binding protein from Brassica pollen for allergen-specific immunotherapy

Immunobiology ◽  
2013 ◽  
Vol 218 (9) ◽  
pp. 1155-1165 ◽  
Author(s):  
Tetiana Garmatiuk ◽  
Ines Swoboda ◽  
Anna Twardosz-Kropfmüller ◽  
Fabio Dall’Antonia ◽  
Walter Keller ◽  
...  
Keyword(s):  
Calcium Binding ◽  
Specific Immunotherapy ◽  
Binding Protein ◽  
Calcium Binding Protein ◽  
Allergen Specific Immunotherapy ◽  
Brassica Pollen

scholarly journals Preparation and Characterization of a Glycyrrhizic Acid-Based Drug Delivery System for Allergen-Specific Immunotherapy

Nanomaterials ◽  
2021 ◽  
Vol 12 (1) ◽  
pp. 148
Author(s):  
Ekaterina Pashkina ◽  
Veronika Evseenko ◽  
Natalya Dumchenko ◽  
Maxim Zelikman ◽  
Alina Aktanova ◽  
...  
Keyword(s):  
Side Effects ◽  
Delivery System ◽  
Glycyrrhizic Acid ◽  
Specific Immunotherapy ◽  
Allergic Diseases ◽  
Treg Cells ◽  
Delivery Systems ◽  
New Drugs ◽  
Allergen Specific Immunotherapy

The most effective method of treating allergic diseases, aimed not at relieving symptoms, but at eliminating the cause of the disease, is allergen-specific immunotherapy (AIT). To reduce the risk of side effects and improve the delivery of allergens to the mucosa, various delivery systems, such as liposomes, dendrimers, nanoparticles, etc., can be used. To date, there are data on the creation of delivery systems based on glycyrrhizic acid (GA) and its derivatives, but such a delivery system has not been used for allergen-specific therapy until now. It is also known that GA has an anti-inflammatory effect, shifts the balance towards Th1, and increases the number of Treg cells, meaning that it could potentially enhance the anti-allergic effect of AIT and reduce the risk of unwanted side effects. Thus, the study of the immunomodulatory effect of the supramolecular complexes (micelles) of GA with extracts of allergens holds promise for the development of new drugs for AIT.

Characterization of mutant ß-Catenin as a target molecule for antigen-specific immunotherapy in Wilms tumors

2004 ◽  
Vol 216 (03) ◽  
Author(s):  
D Ehrlich ◽  
M Thome ◽  
M von Knebel Doeberitz ◽  
R Koesters
Keyword(s):  
Specific Immunotherapy ◽  
Target Molecule
Sign in / Sign up

Export Citation Format

Share Document